1
|
Goodkin K, Vitiello B, Lyman WD, Asthana D, Atkinson JH, Heseltine PNR, Molina R, Zheng W, Khamis I, Wilkie FL, Shapshak P. Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. J Neurovirol 2006; 12:178-89. [PMID: 16877299 DOI: 10.1080/13550280600827344] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
D-Ala1-peptide T-amide (DAPTA) has shown neuroprotection in vitro against gp120-induced loss of dendritic arborization and is promulgated as a CCR5 antagonist. A multisite, randomized, double-blind clinical trial of DAPTA versus placebo prior to combination antiretroviral therapy conducted with human immunodeficiency virus (HIV)-1 seropositive participants having cognitive impairment showed no overall cognitive effect, though subgroups with greater impairment and CD4 cell counts of 201 to 500 cells/mm3 at baseline showed significant improvement. The objective of this study was to examine whether intranasal administration of DAPTA at a dose of 2 mg three times per day (tid) was associated with a reduction of cerebrospinal fluid (CSF) and peripheral (plasma and serum) viral load among a subgroup of participants completing 6 months of treatment. Baseline and 6-month CSF (n = 92) and peripheral (plasma n = 33; serum n = 24) viral load were measured by the Roche Ultrasensitive assay, version 1.5, with reflexive use of the AMPLICOR assay and preservation of the blind. A DAPTA treatment indicator variable was tested using generalized linear models on change in viral load. Peripheral load (combined plasma and serum) was significantly reduced in the DAPTA-treated group. No group differences in CSF viral load were found. This retrospective study on a limited subgroup of the original trial sample indicated that DAPTA treatment may reduce peripheral viral load without concomitant CSF effects. Future studies should be undertaken to confirm the existence of this result and the CSF-periphery dissociation observed with respect to HIV-1-associated cognitive-motor impairment.
Collapse
Affiliation(s)
- Karl Goodkin
- Department of Psychiatry and Behavioral Sciences, University if Miami School of Medicine, Miami, Florida 33136, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Polianova MT, Ruscetti FW, Pert CB, Ruff MR. Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA). Antiviral Res 2005; 67:83-92. [PMID: 16002156 DOI: 10.1016/j.antiviral.2005.03.007] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2004] [Revised: 03/14/2005] [Accepted: 03/18/2005] [Indexed: 10/25/2022]
Abstract
The chemokine receptor CCR5 plays a crucial role in transmission of HIV isolates, which predominate in the early and middle stages of infection, as well as those, which populate the brain and cause neuro-AIDS. CCR5 is therefore an attractive therapeutic target for design of entry inhibitors. Specific rapid filtration binding assays have been useful for almost 30 years both for drug discovery and understanding molecular mechanisms of drug action. Reported in 1986, prior to discovery of chemokine co-receptors and so thought to act at CD4, peptide T (DAPTA) appears to greatly reduce cellular viral reservoirs in both HAART experienced and treatment naïve patients, without toxicities. We here report that DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50=0.06 nM) and CM235 (IC50=0.32 nM) to CCR5. In co-immunoprecipitation studies, DAPTA (1 nM) blocks formation of the gp120/sCD4 complex with CCR5. Confocal microscopic studies of direct FITC-DAPTA binding to CCR5+, but not CCR5-, cells show that CCR5 is a DAPTA receptor. The capability of DAPTA to potently block gp120-CD4 binding to the major co-receptor CCR5 explains its molecular and therapeutic mechanism of action as a selective antiviral entry inhibitor for R5 tropic HIV-1 isolates.
Collapse
Affiliation(s)
- Maria T Polianova
- Department of Physiology and Biophysics, Basic Science, Room 215, Georgetown University School of Medicine, 3900 Reservoir Road, NW, Washington, DC 20007, USA
| | | | | | | |
Collapse
|
3
|
Abstract
A broad range of structural, functional, and immunological similarities between HIV-1 gp120 and human proteins, especially those participating in immune responses, highlight gp120 as a pleiotropic protein that can in different ways affect many important functions of the human immune system. Here we described some of these properties of HIV-1 gp120 that represent the main obstacle in the development of effective and safe AIDS vaccine.
Collapse
Affiliation(s)
- Veljko Veljkovic
- Center for Multidisciplinary Research, Institute of Nuclear Sciences VINCA, Belgrade, Yugoslavia.
| | | | | |
Collapse
|
4
|
Ruff MR, Melendez-Guerrero LM, Yang QE, Ho WZ, Mikovits JW, Pert CB, Ruscetti FA. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res 2001; 52:63-75. [PMID: 11530189 DOI: 10.1016/s0166-3542(01)00163-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Peptide T, which is derived from the V2 region of HIV-1, inhibits replication of R5 and dual-tropic (R5/X4) HIV-1 strains in monocyte-derived macrophages (MDMs), microglia, and primary CD4(+)T cells. Little to no inhibition by peptide T was observed with lab adapted X4 viruses such as IIIB, MN, or NL4-3 propagated in CD4(+) T cells or in the MAGI entry assay. The more clinically relevant R5/X4 early passage patient isolates were inhibited via either the X4 or R5 chemokine receptors, although inhibition was greater with R5 compared to X4 receptors. Virus inhibition ranged from 60 to 99%, depending on the assay, receptor target, viral isolate and amount of added virus. Peak inhibitory effects were detected at concentrations from 10(-12) to 10(-9) M. Peptide T acted to block viral entry as it inhibited in the MAGI cell assay and blocked infection in the luciferase reporter assay using HIV virions pseudotyped with ADA envelope. These results using early passage virus grown in primary cells, together with two different entry reporter assays, show that peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4, explaining past inconsistencies of in vitro antiviral effects.
Collapse
Affiliation(s)
- M R Ruff
- Department of Physiology and Biophysics, Basic Science Building, Room 215, Georgetown University School of Medicine, 3900 Reservoir Road, NW, Washington, DC 20007, USA.
| | | | | | | | | | | | | |
Collapse
|
5
|
The HIV gp120-CD4 interaction: A target for pharmacological or immunological intervention? ACTA ACUST UNITED AC 1993. [DOI: 10.1007/bf02171665] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
6
|
Hill JM, Mervis RF, Avidor R, Moody TW, Brenneman DE. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res 1993; 603:222-33. [PMID: 8461978 DOI: 10.1016/0006-8993(93)91241-j] [Citation(s) in RCA: 103] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Cognitive and motor impairment are common symptoms among patients infected with the human immunodeficiency virus (HIV), including children who suffer neurological deficits and are frequently developmentally impaired. The HIV envelope protein, gp120, which has been shown to be toxic to neurons in culture, is shed in abundance by infected cells, and thus may play a significant role in the neuropathology of AIDS. To test this possible mechanism, neonatal rats were injected systemically with purified gp120 and the following consequences were observed: (1) radiolabeled gp120 and toxic fragments thereof were recovered in brain homogenates; (2) dystrophic changes were produced in pyramidal neurons of cerebral cortex; (3) retardation was evident in developmental milestones associated with complex motor behaviors. In parallel studies, co-treatment with peptide T, a gp120-derived peptide having a pentapeptide sequence homologous with vasoactive intestinal peptide, prevented or attenuated the morphological damage and behavioral delays associated with gp120 treatment. These studies suggest that gp120 and gp120-derived toxic fragments may contribute to the neurological and neuropsychiatric impairment related to HIV infection, and that peptide T appears to be effective in preventing gp120-associated neurotoxicity in developing rodents.
Collapse
Affiliation(s)
- J M Hill
- Unit on Neurochemistry, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892
| | | | | | | | | |
Collapse
|
7
|
Licht D, Cronstein B, Dykes DC, Pedersen J, Luster SM, Trampota M, Hull E, Friedman FK, Pincus MR. Correlation of the conformation of a modified ribonuclease octapeptide, homologous to peptide T, with its ability to induce CD4-dependent monocyte chemotaxis. JOURNAL OF PROTEIN CHEMISTRY 1992; 11:475-81. [PMID: 1449597 DOI: 10.1007/bf01025024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Peptide T, from the human immunodeficiency virus (HIV), whose sequence is Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr, has been shown to inhibit attachment of this virus to T cells and neural cells bearing the CD4 receptor. This peptide shares extensive homology with the 19-26 segment of ribonuclease A (RNase A), whose sequence is Ala-Ala-Ser-Ser-Ser-Asn-Tyr-Cys. Based on comparison of the structures of peptides occurring in proteins of known structure that are homologous to peptide T, viz, RNase A and endothiapepsin and on conformational energy calculations, we predicted that peptide T adopts a structure much like that for residues 19-26 in RNase A. A critical feature is a bend involving residues Thr 4-Asn 7 in peptide T corresponding to Ser 22-Tyr 25 in the RNase A peptide. Our proposed structure for peptide T has recently been confirmed by Cotelle et al. (Biochem. Biophys. Res. Commun. 171, 596-602). We now show directly that the RNase A peptide, with Met replacing Cys 26 to prevent disulfide exchange reactions, strongly induces monocyte-chemotaxis that is blocked by anti-CD4 monoclonal antibody. Both peptide T and RNase A fail to induce chemotaxis, however, in neutrophils which do not express surface CD4 receptors. These results suggest that both peptides interact with the CD4 receptor in inducing monocyte chemotaxis. We have also prepared cyclo-RNase A peptide with Met 26. Using molecular dynamics and conformational energy calculations, we find that the cyclic peptide cannot form a bend structure involving Ser 22-Tyr 25 that is superimposable on the RNase A bend.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- D Licht
- Heterocycle Research Corp, New City, New York 10956
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
van den Heever LH, Jordaan JH, Dubery IA. Synthesis and binding of peptide T and aminoacyl derivatives to CD4+ lymphocytes. ACTA ACUST UNITED AC 1992; 24:337-9. [PMID: 1346383 DOI: 10.1016/0020-711x(92)90267-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
1. Peptide T and four other aminoacyl derivatives of this octapeptide were synthesized on solid phase support using the Boc and Fmoc procedures. 2. The octapeptides were modified by chloroacetylation and radiolabelled by halogen exchange with 125I. 3. Purified and crude extracts of lymphocytes were used to determine the binding of the octapeptides at different concentrations.
Collapse
Affiliation(s)
- L H van den Heever
- Department of Biochemistry, Delta G Scientific, Johannesburg, South Africa
| | | | | |
Collapse
|
9
|
Autiero M, Abrescia P, Dettin M, Di Bello C, Guardiola J. Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of the HIV-1 envelope protein. Virology 1991; 185:820-8. [PMID: 1720590 DOI: 10.1016/0042-6822(91)90553-n] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The interaction between the viral envelope protein gp120 and the cellular surface antigen CD4 is a key event in HIV-1 infection. Reciprocal high affinity binding sites have been located in the first domain of CD4 and in the carboxy-terminal region of gp120, respectively. Upon infection, the membranes of the target cells fuse; sites of CD4 and gp120, distinct from their high affinity binding sites, play a role in the post-binding events leading to syncytia formation. We have studied the interactions of CD4 with gp120 and gp120-derived peptides using an in vitro assay based on immobilized recombinant soluble CD4 (sCD4). In this system CD4 binds to recombinant soluble gp120 and to anti-receptor peptides derived from the high affinity CD4-binding site of gp120, as well as to peptides corresponding to the principal neutralizing domain (PND) of the envelope protein, i.e., to the domain required for HIV-1-mediated syncytium formation. Competition experiments performed using epitope-specific mAbs and a variety of peptides indicated that PND-derived peptides are specifically recognized by a CD4 site adjacent to, but distinct from, the high affinity gp120-binding site of CD4. Synthetic peptides patterned on the PND of different viral isolates were retained onto sCD4-based affinity columns at different extent; some of the structural requirements for binding were analyzed. Studies performed on CD4+ T-cells showed that PND-derived peptides also interact with CD4 in its native membrane-bound conformation. These results indicate that a direct contact takes place between CD4 and the gp120 domain participating in HIV-induced syncytia formation.
Collapse
Affiliation(s)
- M Autiero
- International Institute of Genetics and Biophysics, CNR, Naples, Italy
| | | | | | | | | |
Collapse
|
10
|
Affiliation(s)
- M K Sachs
- Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania
| | | |
Collapse
|
11
|
Julander I, Alexius B, Britton S, Ehrnst A, Jorup-Rönström C, Kjellman B, Strannegård Ö, Sääf J, Sönnerborg A, Wahlund LO, Wetterberg L. Treatment of HIV-1 Infected Patients with Peptide T. Antivir Chem Chemother 1990. [DOI: 10.1177/095632029000100602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
In a pilot study 10 human immunodeficiency virus type 1 (HlV-1)-infected patients were studied. Three CDC group IVa and four CDC group IVc patients were treated with the octapeptide T (D-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-NH2) by intravenous infusion for 4 weeks. Three CDC group IVa patients served as controls and received placebo. HIV was isolated from the blood of all patients before as well as after treatment. In two of five peptide T-treated patients with demonstrable HIV p24 antigen in serum there was a significant decline of antigen levels followed by a rise after discontinuation of treatment. There was a transient rise in the CD4+ cell count in three of the treated patients and a continuous significant decline in one of the control patients. Of the six peptide T-treated patients, evaluated by MRI, four had reduced the area of altered brain white matter. Also, there was a tendency towards improvement of neuropsychiatric symptoms in the treated group of patients. One patient showed improvement of psoriatic lesions during peptide T treatment. Taken together, the data indicated improvement in four of seven treated patients but in none of the controls. These results do not constitute firm evidence that peptide T has clinical or antiviral effect in HIV-1 infecton. However, in view of its apparent non-toxicity and in particular its possible effect on CNS function, expanded clinical trials with peptide T seem justified.
Collapse
Affiliation(s)
- I. Julander
- The Department of Infectious Diseases, Roslagstull Hospital, Karolinska Institute, Danderyd's Hospital, Sweden
| | - B. Alexius
- The Department of Psychiatry, St Göran's Hospital, Karolinska Institute, Danderyd's Hospital, Sweden
| | - S. Britton
- The Department of Infectious Diseases, Roslagstull Hospital, Karolinska Institute, Danderyd's Hospital, Sweden
| | - A. Ehrnst
- The Department of Virology, the Central Microbiological Laboratory of the Stockholm County Council, Danderyd's Hospital, Sweden
| | | | - B. Kjellman
- The Department of Psychiatry, St Göran's Hospital, Karolinska Institute, Danderyd's Hospital, Sweden
| | - Ö. Strannegård
- The Department of Virology, the Central Microbiological Laboratory of the Stockholm County Council, Danderyd's Hospital, Sweden
| | - J. Sääf
- The Department of Psychiatry, St Göran's Hospital, Karolinska Institute, Danderyd's Hospital, Sweden
| | - A. Sönnerborg
- The Department of Infectious Diseases, Roslagstull Hospital, Karolinska Institute, Danderyd's Hospital, Sweden
- The Department of Virology, the Central Microbiological Laboratory of the Stockholm County Council, Danderyd's Hospital, Sweden
| | | | - L. Wetterberg
- The Department of Psychiatry, St Göran's Hospital, Karolinska Institute, Danderyd's Hospital, Sweden
| |
Collapse
|
12
|
Cotelle N, Lohez M, Cotelle P, Hénichart JP. Conformational study of the threonine-rich C-terminal pentapeptide of peptide T. Biochem Biophys Res Commun 1990; 171:596-602. [PMID: 2119576 DOI: 10.1016/0006-291x(90)91188-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The conformation of the synthetic pentapeptide Thr-Thr-Asn-Tyr-Thr, the C-terminal part of peptide T has been studied using 2D NMR experiments. The nuclear Overhauser effects (NOESY) and the low temperature coefficients for two particular NH chemical shifts allow the proposal for two distinct beta-turn arrangements. This conformation is not in accordance with recent reports but is consistent with observed beta-bends in two sequences of ribonuclease A. The semi-rigid conformation found in the pentapeptide in which the hydroxyl groups are exposed at the periphery of the molecule could be a crucial feature to explain the ability of peptide T to bind to a specific receptor and to correlate with the observed biological activity against HIV.
Collapse
|
13
|
Acquired immune deficiency syndrome and the developing nervous system. INTERNATIONAL REVIEW OF NEUROBIOLOGY 1990; 32:305-53. [PMID: 1981886 DOI: 10.1016/s0074-7742(08)60587-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
14
|
Torensma R, van der Bij W. Limiting HIV infectivity with peptides. IMMUNOLOGY TODAY 1988; 9:255-6. [PMID: 3267135 DOI: 10.1016/0167-5699(88)91301-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
15
|
Chapter 17. Antiviral Agents. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1988. [DOI: 10.1016/s0065-7743(08)60845-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|
16
|
|